Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.

Fix AD, Harro C, McNeal M, Dally L, Flores J, Robertson G, Boslego JW, Cryz S.

Vaccine. 2015 Jul 17;33(31):3766-72. doi: 10.1016/j.vaccine.2015.05.024. Epub 2015 Jun 8.

2.

PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries.

Neuzil KM, Tsvetnitsky V, Nyari LJ, Bright RA, Boslego JW; PATH's Influenza Vaccine Project team.

Expert Rev Vaccines. 2012 Aug;11(8):939-47.

PMID:
23002975
3.

Profile: PATH's Vaccine Development Global Program.

Boslego JW.

Hum Vaccin Immunother. 2012 Jun;8(6):700-1. doi: 10.4161/hv.21033. Epub 2012 Jun 1. No abstract available.

PMID:
22699437
4.

Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.

Diaz-Mitoma F, Halperin SA, Tapiero B, Hoffenbach A, Zappacosta PS, Radley D, Bradshaw S, Martin JC, Boslego JW, Hesley TM, Bhuyan PK, Silber JL.

Vaccine. 2011 Feb 1;29(6):1324-31. doi: 10.1016/j.vaccine.2010.11.053. Epub 2010 Dec 4.

PMID:
21134456
5.

Strategies for broad global access to pandemic influenza vaccines.

Edwards KM, Sabow A, Pasternak A, Boslego JW.

Curr Top Microbiol Immunol. 2009;333:471-93. doi: 10.1007/978-3-540-92165-3_23. Review.

PMID:
19768420
6.

Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.

Halperin SA, Tapiero B, Diaz-Mitoma F, Law BJ, Hoffenbach A, Zappacosta PS, Radley D, McCarson BJ, Martin JC, Brackett LE, Boslego JW, Hesley TM, Bhuyan PK, Silber JL.

Vaccine. 2009 Apr 28;27(19):2540-7. doi: 10.1016/j.vaccine.2008.11.115. Epub 2009 Jan 3.

PMID:
19124057
7.

Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults.

Van Damme P, Minervini G, Liss CL, McCarson B, Vesikari T, Boslego JW, Bhuyan PK.

Hum Vaccin. 2009 Feb;5(2):92-7. Epub 2009 Feb 14. Erratum in: Hum Vaccin Immunother. 2017 Apr 3;13(4):965.

PMID:
18690015
8.

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.

Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM, DiNubile MJ; REST Study Team.

Pediatr Infect Dis J. 2007 Dec;26(12):1099-104.

PMID:
18043445
9.

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.

Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J.

Lancet. 2007 May 19;369(9574):1693-702.

PMID:
17512854
10.

Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States.

Rodriguez ZM, Goveia MG, Stek JE, Dallas MJ, Boslego JW, DiNubile MJ, Heaton PM.

Pediatr Infect Dis J. 2007 Mar;26(3):221-7.

PMID:
17484218
11.

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.

Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM; Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group.

Pediatrics. 2007 Jan;119(1):11-8.

PMID:
17200266
12.

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team.

N Engl J Med. 2006 Jan 5;354(1):23-33.

13.

Post-licensure comparative study of unusual high-pitched crying and prolonged crying following COMVAX and placebo versus PedvaxHIB and RECOMBIVAX HB in healthy infants.

Kaplan KM, Rusche SA, Lakkis HD, Bottenfield G, Guerra FA, Guerrero J, Keyserling H, Felicione E, Hesley TM, Boslego JW.

Vaccine. 2002 Dec 13;21(3-4):181-7.

PMID:
12450692
14.

Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers.

Schmidt KA, Schneider H, Lindstrom JA, Boslego JW, Warren RA, Van de Verg L, Deal CD, McClain JB, Griffiss JM.

Sex Transm Dis. 2001 Oct;28(10):555-64.

PMID:
11689753
15.

The effectiveness of Haemophilus influenzae type b conjugate vaccines in a high risk population measured using immunization register data.

Markey P, Krause V, Boslego JW, Coplan PM, Dargan JM, Kaplan KM.

Epidemiol Infect. 2001 Feb;126(1):31-6.

16.

Inflammatory cytokines produced in response to experimental human gonorrhea.

Ramsey KH, Schneider H, Cross AS, Boslego JW, Hoover DL, Staley TL, Kuschner RA, Deal CD.

J Infect Dis. 1995 Jul;172(1):186-91.

PMID:
7797909
17.

Experimental human gonococcal urethritis: 250 Neisseria gonorrhoeae MS11mkC are infective.

Schneider H, Cross AS, Kuschner RA, Taylor DN, Sadoff JC, Boslego JW, Deal CD.

J Infect Dis. 1995 Jul;172(1):180-5.

PMID:
7797908
18.

Public health implications of emerging vaccine technologies.

Lawrence DN, Goldenthal KL, Boslego JW, Chandler DK, La Montagne JR.

Pharm Biotechnol. 1995;6:43-60. Review.

PMID:
7551229
19.

Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.

Brown AE, Singharaj P, Webster HK, Pipithkul J, Gordon DM, Boslego JW, Krinchai K, Su-archawaratana P, Wongsrichanalai C, Ballou WR, et al.

Vaccine. 1994 Feb;12(2):102-8.

PMID:
8147091
20.

Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand.

Clendennen TE, Echeverria P, Saengeur S, Kees ES, Boslego JW, Wignall FS.

Antimicrob Agents Chemother. 1992 Aug;36(8):1682-7.

21.

Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men.

Schneider H, Griffiss JM, Boslego JW, Hitchcock PJ, Zahos KM, Apicella MA.

J Exp Med. 1991 Dec 1;174(6):1601-5.

22.

Efficacy trial of a parenteral gonococcal pilus vaccine in men.

Boslego JW, Tramont EC, Chung RC, McChesney DG, Ciak J, Sadoff JC, Piziak MV, Brown JD, Brinton CC Jr, Wood SW, et al.

Vaccine. 1991 Mar;9(3):154-62.

PMID:
1675029
23.

Human immunization with Pgh 3-2 gonococcal pilus results in cross-reactive antibody to the cyanogen bromide fragment-2 of pilin.

Johnson SC, Chung RC, Deal CD, Boslego JW, Sadoff JC, Wood SW, Brinton CC Jr, Tramont EC.

J Infect Dis. 1991 Jan;163(1):128-34.

PMID:
1701817
24.

A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of uncomplicated male urethritis.

Boslego JW, Hicks CB, Greenup R, Thomas RJ, Wiener HA, Ciak J, Tramont EC.

Sex Transm Dis. 1988 Oct-Dec;15(4):186-91.

PMID:
3147522
25.

Spectinomycin disk zone diameter as a predictor of outcome in clinical treatment of gonorrhea.

McChesney DG, Boslego JW, Khan WN.

Antimicrob Agents Chemother. 1988 May;32(5):775-6.

26.

Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae.

Boslego JW, Tramont EC, Takafuji ET, Diniega BM, Mitchell BS, Small JW, Khan WN, Stein DC.

N Engl J Med. 1987 Jul 30;317(5):272-8.

PMID:
2955222
27.

Evidence of serum antibodies to Neisseria gonorrhoeae before gonococcal infection.

Hicks CB, Boslego JW, Brandt B.

J Infect Dis. 1987 Jun;155(6):1276-81.

PMID:
2883240
28.

Pathogenesis and management of gonorrhea.

Tramont EC, Boslego JW.

Adv Exp Med Biol. 1987;224:117-26. Review. No abstract available.

PMID:
3130748
29.

Pilus vaccines.

Tramont EC, Boslego JW.

Vaccine. 1985 Mar;3(1):3-10. Review.

PMID:
2408396
30.

Genital antibody response to a parenteral gonococcal pilus vaccine.

McChesney D, Tramont EC, Boslego JW, Ciak J, Sadoff J, Brinton CC.

Infect Immun. 1982 Jun;36(3):1006-12.

31.

Gonococcal pilus vaccine. Studies of antigenicity and inhibition of attachment.

Tramont EC, Sadoff JC, Boslego JW, Ciak J, McChesney D, Brinton CC, Wood S, Takafuji E.

J Clin Invest. 1981 Oct;68(4):881-8.

32.

Supplemental Content

Loading ...
Support Center